These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11587283)

  • 1. COX-2 inhibition and thrombotic tendency: a need for surveillance.
    Cleland LG; James MJ; Stamp LK; Penglis PS
    Med J Aust; 2001 Aug; 175(4):214-7. PubMed ID: 11587283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.
    Budenholzer BR
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12130617
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective COX-2 inhibitors.
    Pasero C; McCaffery M
    Am J Nurs; 2001 Apr; 101(4):55-6. PubMed ID: 11301685
    [No Abstract]   [Full Text] [Related]  

  • 6. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
    Chiolero A; Maillard MP; Burnier M
    Expert Opin Drug Saf; 2002 May; 1(1):45-52. PubMed ID: 12904159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 12. COX-2 inhibitors. Magic bullets or merely mortal?
    Harv Health Lett; 2000 Feb; 25(4):4. PubMed ID: 10637015
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical pharmacology of the selective COX-2 inhibitors].
    Burian M; Geisslinger G
    Orthopade; 2003 Dec; 32(12):1078-87. PubMed ID: 14655004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of cardiovascular events associated with selective COX-2 inhibitors.
    Mukherjee D; Nissen SE; Topol EJ
    JAMA; 2001 Aug 22-29; 286(8):954-9. PubMed ID: 11509060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Side effects cause enormous costs. Expensive arthritis therapy].
    MMW Fortschr Med; 2001 Nov; 143(46):60. PubMed ID: 11759607
    [No Abstract]   [Full Text] [Related]  

  • 16. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wooltorton E
    CMAJ; 2002 Jun; 166(13):1692-3. PubMed ID: 12126328
    [No Abstract]   [Full Text] [Related]  

  • 17. Celecoxib and rofecoxib.
    Brinker AD; Bonnel RA; Feight AG; Nourjah P
    J Am Dent Assoc; 2001 Nov; 132(11):1502, 1504. PubMed ID: 11806062
    [No Abstract]   [Full Text] [Related]  

  • 18. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.